USAntibiotics, an American maker of penicillin-based Amoxicillin and Amoxil Clavulanate, has reopened its Bristol, Tenn. manufacturing facility, which had slipped into bankruptcy and ceased operations last year. The event marks the first time the facility is under American ownership. 
 
When the 360,000-square foot facility comes online, it will have the capacity to produce 300 million capsules and two billion tablets annually and can manufacture and stockpile a five-year supply of Amoxicillin for the United States.  
 
Thirty percent of all antibiotics prescribed in the United States each year are Amoxicillin. Upon reopening, USAntibiotics will be the only American company able to manufacture this life saving antibiotic. At full capacity, the facility in Bristol, TN will be able to meet 100 percent of the nation’s demand for Amoxicillin. Every dose of Amoxicillin that will be needed in the United States over the next five years can be manufactured and stored at the USAntibiotics facility, supplying the entire U.S. strategic stockpile. This shift is a complete reversal of the current situation where every dose is sourced from outside the USA. 
 
Bringing Pharmaceutical Production Back to the USA
 
“Our mission is to solve our nation’s reliance on foreign Amoxicillin and create a secure stockpile that will stand the test of time. Beginning today, the United States is back in the business of essential medicines,” said Rick Jackson, founder, CEO, and chairman of Jackson Healthcare, which purchased the Bristol facility from bankruptcy earlier this year.
 
In 2008, every U.S.-administered dose of Amoxil and Augmentin was produced in America. After years of declining pharmaceutical production capacity, American healthcare has had to source every capsule of these life-saving drugs from foreign countries, primarily China.
 
Earlier this year, President Joe Biden directed his administration to conduct a review of crucial U.S. supply chains, including pharmaceuticals. Foreign pharmaceutical supply chain consolidation has made essential medicines and raw materials acutely vulnerable to disruptions from mismanagement, natural disasters, pandemics and economic weaponization.
 
The USAntibiotics antibiotics manufacturing facility is among the first wave of private-sector action to strengthen, secure and advance America’s pharmaceutical production capacity.
 
Federal and statewide elected officials, including Tennessee Governor Bill Lee and Congresswoman Diana Harshbarger, will participate in a ceremonial ribbon cutting alongside USAntibiotics associates and representatives from Jackson Healthcare later today.